jm8b00664_si_006.pdb (135.61 kB)
Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
dataset
posted on 2018-07-25, 00:00 authored by Shipeng He, Guoqiang Dong, Shanchao Wu, Kun Fang, Zhenyuan Miao, Wei Wang, Chunquan Shengp53-Murine double
minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important
targets in antitumor drug development. Inspired by the synergistic
effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors
were identified, which showed excellent activities against both targets.
In particular, compound 14d was proven to be a potent
and orally active MDM2/HDAC dual inhibitor, whose antitumor mechanisms
were validated in cancer cells. Compound 14d showed excellent
in vivo antitumor potency in the A549 xenograft model, providing a
promising lead compound for the development of novel antitumor agents.
Also, this proof-of-concept study offers a novel and efficient strategy
for multitargeting antitumor drug discovery.
History
Usage metrics
Categories
Keywords
antitumor drug developmentSmall Moleculescompound 14cancer cellsHDACantitumor mechanismsminute 2Inhibiting p 53-Murine Double Minute 2Compound 14multitargeting antitumor drug discoveryMDM 2proof-of-concept studyvivo antitumor potencyHistone DeacetylasesNovel Multitargeting Antitumor Agents p 53-Murine549 xenograft modelhistone deacetylasesnovel antitumor agentsinhibitor
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC